JP2007530540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530540A5 JP2007530540A5 JP2007504971A JP2007504971A JP2007530540A5 JP 2007530540 A5 JP2007530540 A5 JP 2007530540A5 JP 2007504971 A JP2007504971 A JP 2007504971A JP 2007504971 A JP2007504971 A JP 2007504971A JP 2007530540 A5 JP2007530540 A5 JP 2007530540A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- hiv
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55576704P | 2004-03-24 | 2004-03-24 | |
| US60/555,767 | 2004-03-24 | ||
| PCT/US2005/006277 WO2005102392A2 (en) | 2004-03-24 | 2005-03-01 | Combinations for treating hiv infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530540A JP2007530540A (ja) | 2007-11-01 |
| JP2007530540A5 true JP2007530540A5 (https=) | 2008-04-17 |
| JP4847441B2 JP4847441B2 (ja) | 2011-12-28 |
Family
ID=34961940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504971A Expired - Lifetime JP4847441B2 (ja) | 2004-03-24 | 2005-03-01 | Ｈｉｖ感染の治療方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7776863B2 (https=) |
| EP (1) | EP1732604B1 (https=) |
| JP (1) | JP4847441B2 (https=) |
| KR (1) | KR101158140B1 (https=) |
| CN (1) | CN1956720B (https=) |
| AR (1) | AR048333A1 (https=) |
| AT (1) | ATE474602T1 (https=) |
| AU (1) | AU2005235116B2 (https=) |
| BR (1) | BRPI0509140A (https=) |
| CA (1) | CA2561146C (https=) |
| CY (1) | CY1111613T1 (https=) |
| DE (1) | DE602005022420D1 (https=) |
| DK (1) | DK1732604T3 (https=) |
| ES (1) | ES2347801T3 (https=) |
| GE (1) | GEP20104925B (https=) |
| HR (1) | HRP20100434T1 (https=) |
| IL (1) | IL178141A (https=) |
| IN (1) | IN2012DN06436A (https=) |
| MY (1) | MY144318A (https=) |
| NO (1) | NO337116B1 (https=) |
| NZ (1) | NZ549778A (https=) |
| PE (1) | PE20060148A1 (https=) |
| PL (1) | PL1732604T3 (https=) |
| PT (1) | PT1732604E (https=) |
| RU (1) | RU2367439C2 (https=) |
| SI (1) | SI1732604T1 (https=) |
| TW (1) | TWI347184B (https=) |
| UA (1) | UA88463C2 (https=) |
| WO (1) | WO2005102392A2 (https=) |
| ZA (1) | ZA200607959B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7501419B2 (en) * | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7572810B2 (en) * | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| US7504399B2 (en) | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| JP5433691B2 (ja) * | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体 |
| JP5433690B2 (ja) | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | 抗−ｈｉｖ薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン |
| US20110293686A1 (en) * | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| WO2012019003A1 (en) | 2010-08-06 | 2012-02-09 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
| WO2012106189A1 (en) | 2011-01-31 | 2012-08-09 | Bristol-Myers Squibb Company | Methods of making hiv attachment inhibitor prodrug compound and intermediates |
| ES2636312T3 (es) | 2011-04-12 | 2017-10-05 | VIIV Healthcare UK (No.5) Limited | Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH |
| ES2609579T3 (es) | 2011-08-29 | 2017-04-21 | VIIV Healthcare UK (No.5) Limited | Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH |
| EP2751119B1 (en) | 2011-08-29 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| WO2013138436A1 (en) | 2012-03-14 | 2013-09-19 | Bristol-Myers Squibb Company | Cyclolic hydrazine derivatives as hiv attachment inhibitors |
| ES2616492T3 (es) | 2012-08-09 | 2017-06-13 | VIIV Healthcare UK (No.5) Limited | Derivados de piperidina amida como inhibidores de la fijación del VIH |
| EP2895472B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
| US9586957B2 (en) * | 2013-03-27 | 2017-03-07 | VIIV Healthcare UK (No.5) Limited | 2-keto amide derivatives as HIV attachment inhibitors |
| US11584797B2 (en) | 2015-06-23 | 2023-02-21 | Cytodyn Inc. | Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
| US12425371B2 (en) * | 2022-09-16 | 2025-09-23 | Cisco Technology, Inc. | System and method for providing SCHC-based edge firewalling |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762404B2 (en) * | 1998-03-02 | 2003-06-26 | Panacos Pharmaceuticals, Inc. | Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20030207910A1 (en) * | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| RU2192870C1 (ru) * | 2001-07-02 | 2002-11-20 | Закрытое акционерное общество "Агрофарм ПитерСиб" | Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией |
| JP2005515206A (ja) * | 2001-12-12 | 2005-05-26 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖインテグラーゼ・インヒビター |
| CA2467718C (en) * | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
-
2005
- 2005-02-24 US US11/064,683 patent/US7776863B2/en active Active
- 2005-03-01 CN CN2005800160669A patent/CN1956720B/zh not_active Expired - Lifetime
- 2005-03-01 SI SI200531100T patent/SI1732604T1/sl unknown
- 2005-03-01 WO PCT/US2005/006277 patent/WO2005102392A2/en not_active Ceased
- 2005-03-01 AU AU2005235116A patent/AU2005235116B2/en not_active Expired
- 2005-03-01 UA UAA200611163A patent/UA88463C2/ru unknown
- 2005-03-01 RU RU2006137555/14A patent/RU2367439C2/ru active
- 2005-03-01 PT PT05723932T patent/PT1732604E/pt unknown
- 2005-03-01 GE GEAP20059667A patent/GEP20104925B/en unknown
- 2005-03-01 ES ES05723932T patent/ES2347801T3/es not_active Expired - Lifetime
- 2005-03-01 BR BRPI0509140-3A patent/BRPI0509140A/pt not_active Application Discontinuation
- 2005-03-01 EP EP05723932A patent/EP1732604B1/en not_active Expired - Lifetime
- 2005-03-01 DK DK05723932.9T patent/DK1732604T3/da active
- 2005-03-01 DE DE602005022420T patent/DE602005022420D1/de not_active Expired - Lifetime
- 2005-03-01 IN IN6436DEN2012 patent/IN2012DN06436A/en unknown
- 2005-03-01 NZ NZ549778A patent/NZ549778A/en not_active IP Right Cessation
- 2005-03-01 JP JP2007504971A patent/JP4847441B2/ja not_active Expired - Lifetime
- 2005-03-01 HR HR20100434T patent/HRP20100434T1/hr unknown
- 2005-03-01 PL PL05723932T patent/PL1732604T3/pl unknown
- 2005-03-01 CA CA2561146A patent/CA2561146C/en not_active Expired - Lifetime
- 2005-03-01 AT AT05723932T patent/ATE474602T1/de active
- 2005-03-01 KR KR1020067019595A patent/KR101158140B1/ko not_active Expired - Lifetime
- 2005-03-17 MY MYPI20051136A patent/MY144318A/en unknown
- 2005-03-18 TW TW094108462A patent/TWI347184B/zh not_active IP Right Cessation
- 2005-03-23 AR ARP050101159A patent/AR048333A1/es not_active Application Discontinuation
- 2005-03-28 PE PE2005000344A patent/PE20060148A1/es not_active Application Discontinuation
-
2006
- 2006-09-17 IL IL178141A patent/IL178141A/en active IP Right Review Request
- 2006-09-22 ZA ZA200607959A patent/ZA200607959B/en unknown
- 2006-10-06 NO NO20064547A patent/NO337116B1/no unknown
-
2010
- 2010-10-20 CY CY20101100937T patent/CY1111613T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530540A5 (https=) | ||
| De Clercq | Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF) | |
| RU2006137555A (ru) | Способы и композиции для лечения вич-инфекции | |
| Piacenti | An update and review of antiretroviral therapy | |
| RU2420284C2 (ru) | Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич | |
| Ruela Correa et al. | Darunavir: a critical review of its properties, use and drug interactions | |
| De Clercq | Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections | |
| US20150133434A1 (en) | Compositions and Methods for Reactivating Latent Immunodeficiency Virus | |
| US20150030638A1 (en) | Ingenol Derivatives in the Reactivation of Latent HIV | |
| AU2020228361B2 (en) | Treatment of herpes simplex with a combination of valacyclovir and famciclovir | |
| CA2920811A1 (en) | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir | |
| A Waheed et al. | Why do we need new drug classes for HIV treatment and prevention? | |
| KR102286386B1 (ko) | 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제 | |
| WO2011089166A1 (en) | Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection | |
| US20200101072A1 (en) | Hiv post-exposure prophylaxis | |
| CN111587107A (zh) | 药物组合物 | |
| Roberts et al. | Virologic Failure with a Raltegravir‐Containing Antiretroviral Regimen and Concomitant Calcium Administration | |
| US20160235750A1 (en) | Small molecules targeting hiv-1 nef | |
| Rockstroh et al. | Pharmacokinetics of faldaprevir and antiretrovirals in patients with HIV/HCV Co-infection | |
| JP2020530024A (ja) | 組み合わせ並びにその使用及び治療 | |
| JP2020528413A (ja) | Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン | |
| Sension | Initial Therapy for Human Immunodeficiency Virus: Broadening the Options | |
| Di Biagio et al. | Which patients have greatest need for elvitegravir/cobicistat/emtricitabine/tenofovirDF-based therapy? | |
| HK40065109A (en) | Treatment of herpes simplex with a combination of valacyclovir and famciclovir | |
| JP2020529461A (ja) | 組み合わせ並びにその使用及び治療 |